drugset / Trial / NCT00004688

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

NCT00004688

Phase 2 Completed 35 enrolled Emory University
Treatment

Summary

OBJECTIVES: I. Assess the clinical response of patients with refractory or recurrent brain neoplasms treated with carmustine, streptozocin, and mercaptopurine.

Timeline

Start
1996-08
Primary completion
Completion
1998-07

Drugs

EvaluationDrugModalityDoseRoute
Subject MERCAPTOPURINE ANHYDROUS Small molecule Intravenous
Subject carmustine Small molecule
Subject streptozocin Small molecule Intravenous